vs
Side-by-side financial comparison of HireQuest, Inc. (HQI) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $7.0M, roughly 1.3× HireQuest, Inc.). HireQuest, Inc. runs the higher net margin — 22.8% vs -60.3%, a 83.1% gap on every dollar of revenue. On growth, HireQuest, Inc. posted the faster year-over-year revenue change (-13.0% vs -49.9%). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -8.6%).
Quest, also known as Quest - Hire a Hero, is a Singapore-based technology company founded in 2021 that operates an AI-powered on-demand services marketplace. The platform connects users with verified workers, known as “Heroes” to complete a wide range of tasks.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
HQI vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.0M | $9.1M |
| Net Profit | $1.6M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | 18.6% | -51.1% |
| Net Margin | 22.8% | -60.3% |
| Revenue YoY | -13.0% | -49.9% |
| Net Profit YoY | -27.8% | -184.8% |
| EPS (diluted) | $0.11 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.0M | $9.1M | ||
| Q3 25 | $8.5M | $17.9M | ||
| Q2 25 | $7.6M | $15.7M | ||
| Q1 25 | $7.5M | $10.1M | ||
| Q4 24 | $8.1M | $18.2M | ||
| Q3 24 | $9.4M | $18.0M | ||
| Q2 24 | $8.7M | $13.5M | ||
| Q1 24 | $8.4M | — |
| Q4 25 | $1.6M | $-5.5M | ||
| Q3 25 | $2.3M | $2.4M | ||
| Q2 25 | $1.1M | $164.0K | ||
| Q1 25 | $1.4M | $-3.6M | ||
| Q4 24 | $2.2M | $6.5M | ||
| Q3 24 | $-2.2M | $3.2M | ||
| Q2 24 | $2.0M | $-2.2M | ||
| Q1 24 | $1.6M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | 18.6% | -51.1% | ||
| Q3 25 | 28.8% | 11.9% | ||
| Q2 25 | 13.7% | 7.5% | ||
| Q1 25 | 19.8% | -41.0% | ||
| Q4 24 | 28.0% | 39.6% | ||
| Q3 24 | -28.6% | 22.2% | ||
| Q2 24 | 31.0% | -18.0% | ||
| Q1 24 | 25.0% | — |
| Q4 25 | 22.8% | -60.3% | ||
| Q3 25 | 27.1% | 13.2% | ||
| Q2 25 | 13.9% | 1.0% | ||
| Q1 25 | 18.2% | -35.8% | ||
| Q4 24 | 27.5% | 35.6% | ||
| Q3 24 | -23.4% | 18.0% | ||
| Q2 24 | 23.5% | -16.4% | ||
| Q1 24 | 19.2% | — |
| Q4 25 | $0.11 | $-0.06 | ||
| Q3 25 | $0.16 | $0.03 | ||
| Q2 25 | $0.08 | $0.00 | ||
| Q1 25 | $0.10 | $-0.05 | ||
| Q4 24 | $0.15 | $0.10 | ||
| Q3 24 | $-0.16 | $0.03 | ||
| Q2 24 | $0.15 | $-0.03 | ||
| Q1 24 | $0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $68.3M | $48.2M |
| Total Assets | $88.2M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | — | — |
| Q4 25 | $68.3M | $48.2M | ||
| Q3 25 | $67.8M | $52.9M | ||
| Q2 25 | $66.0M | $49.9M | ||
| Q1 25 | $65.6M | $45.2M | ||
| Q4 24 | $64.8M | $43.2M | ||
| Q3 24 | $62.9M | $32.4M | ||
| Q2 24 | $65.4M | $28.6M | ||
| Q1 24 | $63.9M | — |
| Q4 25 | $88.2M | $82.3M | ||
| Q3 25 | $94.9M | $82.3M | ||
| Q2 25 | $94.3M | $78.5M | ||
| Q1 25 | $93.7M | $73.9M | ||
| Q4 24 | $94.0M | $73.4M | ||
| Q3 24 | $102.7M | $61.6M | ||
| Q2 24 | $107.6M | $91.5M | ||
| Q1 24 | $105.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.6M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | 4.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.6M | $2.0M | ||
| Q3 25 | $1.0M | $-3.7M | ||
| Q2 25 | $2.6M | $-5.2M | ||
| Q1 25 | $1.9M | $-5.1M | ||
| Q4 24 | $8.7M | $4.0M | ||
| Q3 24 | $4.2M | $4.1M | ||
| Q2 24 | $188.0K | $-3.6M | ||
| Q1 24 | $-967.0K | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
| Q4 25 | 4.12× | — | ||
| Q3 25 | 0.45× | -1.58× | ||
| Q2 25 | 2.41× | -31.91× | ||
| Q1 25 | 1.36× | — | ||
| Q4 24 | 3.90× | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | -0.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HQI
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
